Suppr超能文献

开发和验证用于肝细胞癌的免疫和代谢相关预后综合标志物。

Development and Verification of a Combined Immune- and Metabolism-Related Prognostic Signature for Hepatocellular Carcinoma.

机构信息

Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, China.

出版信息

Front Immunol. 2022 Jul 8;13:927635. doi: 10.3389/fimmu.2022.927635. eCollection 2022.

Abstract

Immune escape and metabolic reprogramming are becoming important characteristics of tumor biology, which play critical roles in tumor initiation and progression. However, the integrative analysis of immune and metabolic characteristics for the tumor microenvironment in hepatocellular carcinoma (HCC) remains unclear. Herein, by univariate and least absolute shrinkage and selection operator (LASSO) Cox regression analyses, a prognostic signature associated with tumor microenvironment was established based on five immune- and metabolism-related genes (IMRGs), which was fully verified and evaluated in both internal and external cohorts. The C-index was superior to previously published HCC signatures, indicating the robustness and reliability of IMRGs prognostic signature. A nomogram was built based on IMRGs prognostic signature and various clinical parameters, such as age and T stage. The AUCs of nomogram at 1-, 3-, and 5-year (AUC = 0.829, 0.749, 0.749) were slightly better than that of IMRGs signature (AUC = 0.809, 0.734, 0.711). The relationship of risk score (RS) with immune checkpoint expressions, immunophenoscore (IPS), as well as microsatellite instability (MSI) together accurately predicted the treatment efficacy. Collectively, the IMRGs signature might have the potential to better predict prognostic risk, evaluate immunotherapy efficacy, and help personalize immunotherapy for HCC patients.

摘要

免疫逃逸和代谢重编程正成为肿瘤生物学的重要特征,在肿瘤的发生和发展中起着关键作用。然而,肝癌(HCC)肿瘤微环境中免疫和代谢特征的综合分析仍不清楚。在此,通过单变量和最小绝对值收缩和选择算子(LASSO)Cox 回归分析,基于五个免疫和代谢相关基因(IMRG)建立了与肿瘤微环境相关的预后特征,在内部和外部队列中进行了充分的验证和评估。C 指数优于先前发表的 HCC 特征,表明 IMRGs 预后特征的稳健性和可靠性。基于 IMRGs 预后特征和各种临床参数(如年龄和 T 分期)构建了列线图。列线图在 1、3 和 5 年的 AUC(AUC = 0.829、0.749、0.749)略优于 IMRGs 特征(AUC = 0.809、0.734、0.711)。风险评分(RS)与免疫检查点表达、免疫表型评分(IPS)以及微卫星不稳定性(MSI)的关系可以准确预测治疗效果。总的来说,IMRG 特征可能有潜力更好地预测预后风险、评估免疫治疗效果,并帮助 HCC 患者进行个体化免疫治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e83a/9304746/8f45930a56ac/fimmu-13-927635-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验